Human subject protections
FDA Commissioner Henney will be among witnesses testifying before a Government Reform/Criminal Justice, Drug Policy & Human Resources Subcommittee hearing on institutional review boards and federal protections for human research subjects May 3. Subcommittee Chairman Mica (R-Fla.) called the hearing in response to two Inspector General reports on IRBs (1"The Pink Sheet" April 17, p. 28). Also among the witnesses will be NIH Acting Director Ruth Kirschstein, MD, NIH Office of Protection from Research Risks Acting Director Gary Ellis, PhD and Deputy Inspector General George Grob
You may also be interested in...
FDA and NIH should expand improvement efforts in gene therapy trial oversight to other types of clinical trials, the HHS Inspector General suggested in an update on recommendations for protecting human research subjects.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials